Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025

Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study initiation
anticipated by year-end 2025; second oral amylin receptor agonist (ACCG-3535)
development candidate declared

Read more at globenewswire.com